<p>Axsome Therapeutics, Inc.（納斯達克代碼：AXSM - 獲取免費報告）首席運營官 Mark Jacobson 於 5 月 5 日（星期二）出售了 233 股公司的股票。股票以平均價格 228.18 美元出售，總價值為 53,165.94 美元。交易完成後，首席運營官在公司持有 4,517 股，價值 1,030,689.06 美元。這代表其持股減少了 4.91%。此次出售在提交給證券交易委員會的文件中披露，您可以通過此鏈接訪問該文件。</p>
<p>獲取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
<h2>Axsome Therapeutics 股票下跌 0.3%</h2>
<ul>
<li>生物技術行業正在升温——這兩隻火熱股票脱穎而出</li>
</ul>
<p>AXSM 的股票在星期二的交易時段下跌了 0.64 美元，達到 223.06 美元。該公司的股票交易量為 1,019,532 股，而其平均交易量為 882,597 股。該公司的市值為 114.7 億美元，市盈率為-59.80，貝塔值為 0.59。Axsome Therapeutics, Inc.的 1 年最低價為 96.09 美元，1 年最高價為 234.29 美元。該公司的速動比率為 1.48，流動比率為 1.55，債務與股本比率為 1.38。該公司的 50 日移動平均線為 171.73 美元，200 日移動平均線為 163.34 美元。</p>
<p>Axsome Therapeutics（納斯達克代碼：AXSM - 獲取免費報告）於 5 月 4 日（星期一）發佈了最新的財報。公司報告本季度每股收益為（1.26 美元），低於分析師一致預期的（0.85 美元），差距為（0.41 美元）。該季度的營業收入為 1.912 億美元，而分析師預期為 1.911 億美元。Axsome Therapeutics 的淨利潤率為-26.59%，股本回報率為-246.90%。該公司的季度收入同比增長 57.4%。整體來看，研究分析師預測 Axsome Therapeutics, Inc.在當前財政年度將發佈-1.05 的每股收益。</p>
<h2>分析師評級變動</h2>
<ul>
<li>5 只醫療股票的收益增長超過三位數</li>
</ul>
<p>AXSM 最近成為幾份研究報告的主題。TD Cowen 在週五的研究報告中重申了對 Axsome Therapeutics 股票的 “買入” 評級。Wolfe Research 在 2 月 23 日（星期一）的研究報告中開始覆蓋 Axsome Therapeutics。他們給予該公司 “跑贏大盤” 的評級，並設定 230.00 美元的目標價。加拿大皇家銀行在週二的研究報告中將 Axsome Therapeutics 的目標價從 242.00 美元上調至 302.00 美元，並給予該公司 “跑贏大盤” 的評級。Oppenheimer 在週一的研究報告中設定了 280.00 美元的目標價。最後，Jefferies Financial Group 在週一將 Axsome Therapeutics 的目標價從 245.00 美元上調至 275.00 美元，並給予該公司 “買入” 評級。一位研究分析師對該股票給予了強烈買入評級，十八位分析師給予買入評級，一位給予持有評級，一位給予賣出評級。根據 MarketBeat 的數據，Axsome Therapeutics 的共識評級為 “適度買入”，平均目標價為 251.89 美元。</p>
<p><strong>查看我們對 AXSM 的最新分析</strong></p>
<h2>更多 Axsome Therapeutics 新聞</h2>
<ul>
<li>struggling Axsome 股票可能因藥物試驗成功而反彈</li>
</ul>
<p>以下是本週影響 Axsome Therapeutics 的關鍵新聞：</p>
<ul>
<li>積極情緒：強勁的頂線增長——第一季度淨產品收入為 1.912 億美元，同比增長約 57%，主要得益於 AUVELITY（1.532 億美元）和 SUNOSI（3390 萬美元）；這驗證了 Axsome 主要產品的商業吸引力。Axsome 2026 年第一季度財務結果</li>
<li>積極情緒：今天多位分析師上調了目標價（特別是瑞穗證券至 310 美元，富國銀行至 255 美元，貝爾德至 246 美元，摩根士丹利至 242 美元），持續的 “買入/跑贏大盤” 覆蓋增加了預期上行空間並支持近期情緒。分析師覆蓋與目標價變動</li>
<li>積極情緒：管道和公司催化劑仍在發揮作用——AUVELITY 獲得阿爾茨海默症激動症的批准，AXS-12（猝倒症）的 NDA 提交，AXS-20 的加入——這些可以推動中長期的上行空間。業務更新與管道亮點</li>
<li>中性情緒：管理層外聯：Axsome 將參加多個投資者會議（美銀的爐邊聊天等）——對額外披露有幫助，但時機/影響不確定。投資者會議參與</li>
<li>中性情緒：完整的財報和電話會議記錄可供深入閲讀；分析師和評論員正在詳細分析順序趨勢和指導。財報電話會議記錄與分析</li>
<li>消極情緒：財報未達預期：GAAP 每股收益為（1.26 美元），而共識預期為（約 0.85 美元虧損）——更大的虧損和負利潤率/股本回報率引發了對近期盈利能力的擔憂，儘管收入強勁。第一季度虧損擴大；收入激增（Zacks）</li>
<li>消極情緒：對可持續性的懷疑——評論指出關鍵產品的銷售出現順序下滑，並對管理層長期峯值收入目標的可實現性提出質疑，這可能會抑制熱情。財報回顧與懷疑（Seeking Alpha）</li>
</ul>
<h2>機構投資者對 Axsome Therapeutics 的看法</h2>
<p>一些大型投資者最近增加或減少了對該股票的持股。伊利諾伊州市政退休基金在第一季度購買了 Axsome Therapeutics 的新股份，價值約為 884,000 美元。Hillsdale Investment Management Inc.在第一季度購買了 Axsome Therapeutics 的新股份，價值約為 9,019,000 美元。Fifth Third Bancorp 在第一季度將其在 Axsome Therapeutics 的持股增加了 554.6%。Fifth Third Bancorp 現在擁有 16,214 股該公司的股票，價值 2,741,000 美元，此前在此期間又購買了 13,737 股。滙豐控股 PLC 在第一季度購買了 Axsome Therapeutics 的新股份，價值約為 11,589,000 美元。最後，住友三井信託集團在第一季度將其在 Axsome Therapeutics 的持股增加了 6.8%。住友三井信託集團現在擁有 2,030 股該公司的股票，價值 343,000 美元，此前在此期間又購買了 130 股。機構投資者持有該公司 81.49% 的股票。</p>
<h2>Axsome Therapeutics 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Axsome Therapeutics, Inc 是一家臨牀階段的生物製藥公司，致力於開發針對中樞神經系統（CNS）疾病的新療法。該公司專注於小分子藥物，旨在解決抑鬱症、偏頭痛、嗜睡症和纖維肌痛等領域未滿足的醫療需求。Axsome 採用精準醫學的方法，利用藥理創新來針對疾病的潛在機制並改善患者的治療效果。</p>
<p>Axsome 的產品管線包括多個晚期和已批准的候選產品。</p>
<h2>特色文章</h2>
<ul>
<li>五隻我們認為比 Axsome Therapeutics 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Axsome Therapeutics 嗎？</h2>
<p>在考慮 Axsome Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Axsome Therapeutics 並不在名單上。</p>
<p>雖然 Axsome Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AXSM

<p>Axsome Therapeutics 首席運營官 Mark Jacobson 出售了 233 股股票，平均價格為 228.18 美元，總計 53,165.94 美元。出售後，他持有 4,517 股，價值 1,030,689.06 美元，持股比例減少了 4.91%。該交易已向美國證券交易委員會（SEC）披露。公司的股票下跌 0.3%，報 223.06 美元，市值為 114.7 億美元。Axsome 報告季度每股虧損 1.26 美元，未達到預期，但收入同比增長 57.4%，達到 1.912 億美元。分析師維持 “適度買入” 的共識評級，平均目標價為 251.89 美元</p>

<p>Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 233 shares of the company's stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $228.18, for a total value of $53,165.94. Following the completion of the transaction, the chief operating officer owned 4,517 shares in the company, valued at $1,030,689.06. This represents a 4.91% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc.（納斯達克代碼：AXSM - 獲取免費報告）首席運營官 Mark Jacobson 於 5 月 5 日（星期二）出售了 233 股公司的股票。股票以平均價格 228.18 美元出售，總價值為 53,165.94 美元。交易完成後，首席運營官在公司持有 4,517 股，價值 1,030,689.06 美元。這代表其持股減少了 4.91%。此次出售在提交給證券交易委員會的文件中披露，您可以通過此鏈接訪問該文件。</p>
</div><p>Get <strong>Axsome Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
</div><h2>Axsome Therapeutics Stock Down 0.3%</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 股票下跌 0.3%</h2>
</div><ul>
<li>Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out</li>
</ul>
<div class="lb-trans"><ul>
<li>生物技術行業正在升温——這兩隻火熱股票脱穎而出</li>
</ul>
</div><p>Shares of AXSM traded down $0.64 during trading hours on Tuesday, reaching $223.06. The company's stock had a trading volume of 1,019,532 shares, compared to its average volume of 882,597. The firm has a market cap of $11.47 billion, a price-to-earnings ratio of -59.80 and a beta of 0.59. Axsome Therapeutics, Inc. has a 1-year low of $96.09 and a 1-year high of $234.29. The company has a quick ratio of 1.48, a current ratio of 1.55 and a debt-to-equity ratio of 1.38. The company has a 50 day moving average of $171.73 and a two-hundred day moving average of $163.34.</p>
<div class="lb-trans"><p>AXSM 的股票在星期二的交易時段下跌了 0.64 美元，達到 223.06 美元。該公司的股票交易量為 1,019,532 股，而其平均交易量為 882,597 股。該公司的市值為 114.7 億美元，市盈率為-59.80，貝塔值為 0.59。Axsome Therapeutics, Inc.的 1 年最低價為 96.09 美元，1 年最高價為 234.29 美元。該公司的速動比率為 1.48，流動比率為 1.55，債務與股本比率為 1.38。該公司的 50 日移動平均線為 171.73 美元，200 日移動平均線為 163.34 美元。</p>
</div><p>Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.41). The business had revenue of $191.20 million during the quarter, compared to analyst estimates of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 246.90%. The company's revenue for the quarter was up 57.4% on a year-over-year basis. As a group, research analysts predict that Axsome Therapeutics, Inc. will post -1.05 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Axsome Therapeutics（納斯達克代碼：AXSM - 獲取免費報告）於 5 月 4 日（星期一）發佈了最新的財報。公司報告本季度每股收益為（1.26 美元），低於分析師一致預期的（0.85 美元），差距為（0.41 美元）。該季度的營業收入為 1.912 億美元，而分析師預期為 1.911 億美元。Axsome Therapeutics 的淨利潤率為-26.59%，股本回報率為-246.90%。該公司的季度收入同比增長 57.4%。整體來看，研究分析師預測 Axsome Therapeutics, Inc.在當前財政年度將發佈-1.05 的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只醫療股票的收益增長超過三位數</li>
</ul>
</div><p>AXSM has been the subject of several recent research reports. TD Cowen reissued a &#34;buy&#34; rating on shares of Axsome Therapeutics in a research note on Friday. Wolfe Research initiated coverage on Axsome Therapeutics in a research note on Monday, February 23rd. They issued an &#34;outperform&#34; rating and a $230.00 price target for the company. Royal Bank Of Canada boosted their price target on Axsome Therapeutics from $242.00 to $302.00 and gave the company an &#34;outperform&#34; rating in a research note on Tuesday. Oppenheimer set a $280.00 price target on Axsome Therapeutics in a research note on Monday. Finally, Jefferies Financial Group boosted their price target on Axsome Therapeutics from $245.00 to $275.00 and gave the company a &#34;buy&#34; rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Axsome Therapeutics has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $251.89.</p>
<div class="lb-trans"><p>AXSM 最近成為幾份研究報告的主題。TD Cowen 在週五的研究報告中重申了對 Axsome Therapeutics 股票的 “買入” 評級。Wolfe Research 在 2 月 23 日（星期一）的研究報告中開始覆蓋 Axsome Therapeutics。他們給予該公司 “跑贏大盤” 的評級，並設定 230.00 美元的目標價。加拿大皇家銀行在週二的研究報告中將 Axsome Therapeutics 的目標價從 242.00 美元上調至 302.00 美元，並給予該公司 “跑贏大盤” 的評級。Oppenheimer 在週一的研究報告中設定了 280.00 美元的目標價。最後，Jefferies Financial Group 在週一將 Axsome Therapeutics 的目標價從 245.00 美元上調至 275.00 美元，並給予該公司 “買入” 評級。一位研究分析師對該股票給予了強烈買入評級，十八位分析師給予買入評級，一位給予持有評級，一位給予賣出評級。根據 MarketBeat 的數據，Axsome Therapeutics 的共識評級為 “適度買入”，平均目標價為 251.89 美元。</p>
</div><p><strong>View Our Latest Analysis on AXSM</strong></p>
<div class="lb-trans"><p><strong>查看我們對 AXSM 的最新分析</strong></p>
</div><h2>More Axsome Therapeutics News</h2>
<div class="lb-trans"><h2>更多 Axsome Therapeutics 新聞</h2>
</div><ul>
<li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li>
</ul>
<div class="lb-trans"><ul>
<li>struggling Axsome 股票可能因藥物試驗成功而反彈</li>
</ul>
</div><p>Here are the key news stories impacting Axsome Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本週影響 Axsome Therapeutics 的關鍵新聞：</p>
</div><ul>
<li>Positive Sentiment: Very strong top-line growth — 1Q net product revenue of $191.2M, up ~57% YoY, driven by AUVELITY ($153.2M) and SUNOSI ($33.9M); this validates commercial traction for Axsome’s lead products. Axsome 1Q 2026 Financial Results</li>
<li>Positive Sentiment: Multiple analyst price-target lifts today (notably Mizuho to $310, Wells Fargo to $255, Baird to $246, Morgan Stanley to $242) and continued “buy/outperform” coverage increase perceived upside and support near-term sentiment. Analyst Coverage &amp; Price Target Moves</li>
<li>Positive Sentiment: Pipeline and corporate catalysts remain in play — AUVELITY approval for agitation in Alzheimer’s, NDA submission for AXS‑12 (cataplexy), addition of AXS‑20 to the pipeline — these can drive medium/long-term upside. Business Update &amp; Pipeline Highlights</li>
<li>Neutral Sentiment: Management outreach: Axsome will participate in multiple investor conferences (BofA fireside chat, others) — useful for additional disclosure but timing/impact is uncertain. Investor Conference Participation</li>
<li>Neutral Sentiment: Full earnings and call transcripts are available for deeper read-throughs; analysts and commentators are parsing sequential trends and guidance in detail. Earnings Call Transcript &amp; Analysis</li>
<li>Negative Sentiment: Earnings miss: GAAP EPS of ($1.26) vs. consensus (~$0.85 loss) — the wider loss and negative margins/ROE raise near-term profitability concerns despite revenue strength. Q1 Loss Widens; Revenues Jump (Zacks)</li>
<li>Negative Sentiment: Some skepticism on sustainability — commentary notes sequential sales dips for key products and questions about achievability of management’s long‑term peak revenue targets, which could temper enthusiasm. Earnings Review &amp; Skepticism (Seeking Alpha)</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：強勁的頂線增長——第一季度淨產品收入為 1.912 億美元，同比增長約 57%，主要得益於 AUVELITY（1.532 億美元）和 SUNOSI（3390 萬美元）；這驗證了 Axsome 主要產品的商業吸引力。Axsome 2026 年第一季度財務結果</li>
<li>積極情緒：今天多位分析師上調了目標價（特別是瑞穗證券至 310 美元，富國銀行至 255 美元，貝爾德至 246 美元，摩根士丹利至 242 美元），持續的 “買入/跑贏大盤” 覆蓋增加了預期上行空間並支持近期情緒。分析師覆蓋與目標價變動</li>
<li>積極情緒：管道和公司催化劑仍在發揮作用——AUVELITY 獲得阿爾茨海默症激動症的批准，AXS-12（猝倒症）的 NDA 提交，AXS-20 的加入——這些可以推動中長期的上行空間。業務更新與管道亮點</li>
<li>中性情緒：管理層外聯：Axsome 將參加多個投資者會議（美銀的爐邊聊天等）——對額外披露有幫助，但時機/影響不確定。投資者會議參與</li>
<li>中性情緒：完整的財報和電話會議記錄可供深入閲讀；分析師和評論員正在詳細分析順序趨勢和指導。財報電話會議記錄與分析</li>
<li>消極情緒：財報未達預期：GAAP 每股收益為（1.26 美元），而共識預期為（約 0.85 美元虧損）——更大的虧損和負利潤率/股本回報率引發了對近期盈利能力的擔憂，儘管收入強勁。第一季度虧損擴大；收入激增（Zacks）</li>
<li>消極情緒：對可持續性的懷疑——評論指出關鍵產品的銷售出現順序下滑，並對管理層長期峯值收入目標的可實現性提出質疑，這可能會抑制熱情。財報回顧與懷疑（Seeking Alpha）</li>
</ul>
</div><h2>Institutional Investors Weigh In On Axsome Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Axsome Therapeutics 的看法</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in the stock. Illinois Municipal Retirement Fund bought a new stake in Axsome Therapeutics during the first quarter worth approximately $884,000. Hillsdale Investment Management Inc. bought a new stake in Axsome Therapeutics during the first quarter worth approximately $9,019,000. Fifth Third Bancorp boosted its position in Axsome Therapeutics by 554.6% during the first quarter. Fifth Third Bancorp now owns 16,214 shares of the company's stock worth $2,741,000 after purchasing an additional 13,737 shares during the period. Hsbc Holdings PLC bought a new stake in Axsome Therapeutics during the first quarter worth approximately $11,589,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in Axsome Therapeutics by 6.8% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,030 shares of the company's stock worth $343,000 after purchasing an additional 130 shares during the period. Institutional investors own 81.49% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投資者最近增加或減少了對該股票的持股。伊利諾伊州市政退休基金在第一季度購買了 Axsome Therapeutics 的新股份，價值約為 884,000 美元。Hillsdale Investment Management Inc.在第一季度購買了 Axsome Therapeutics 的新股份，價值約為 9,019,000 美元。Fifth Third Bancorp 在第一季度將其在 Axsome Therapeutics 的持股增加了 554.6%。Fifth Third Bancorp 現在擁有 16,214 股該公司的股票，價值 2,741,000 美元，此前在此期間又購買了 13,737 股。滙豐控股 PLC 在第一季度購買了 Axsome Therapeutics 的新股份，價值約為 11,589,000 美元。最後，住友三井信託集團在第一季度將其在 Axsome Therapeutics 的持股增加了 6.8%。住友三井信託集團現在擁有 2,030 股該公司的股票，價值 343,000 美元，此前在此期間又購買了 130 股。機構投資者持有該公司 81.49% 的股票。</p>
</div><h2>Axsome Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc 是一家臨牀階段的生物製藥公司，致力於開發針對中樞神經系統（CNS）疾病的新療法。該公司專注於小分子藥物，旨在解決抑鬱症、偏頭痛、嗜睡症和纖維肌痛等領域未滿足的醫療需求。Axsome 採用精準醫學的方法，利用藥理創新來針對疾病的潛在機制並改善患者的治療效果。</p>
</div><p>Axsome's pipeline includes several late-stage and approved product candidates.</p>
<div class="lb-trans"><p>Axsome 的產品管線包括多個晚期和已批准的候選產品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Axsome Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Axsome Therapeutics 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=AXSM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Axsome Therapeutics 嗎？</h2>
</div><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Axsome Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Axsome Therapeutics 並不在名單上。</p>
</div><p>While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Axsome Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock

Market Beat

Axsome Therap

加拿大皇家銀行

奧本海默控股

Jefferies Financial

Mizuho Financial Group, Inc.

瑞穗金融集團

富國銀行

摩根士丹利

美國銀行

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

內幕交易：Axsome Therapeutics（NASDAQ:AXSM）的首席運營官出售了 233 股股票